Published in J Pathol on December 01, 1999
The molecular pathology of breast cancer progression. J Pathol (2010) 1.65
CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. Br J Cancer (2001) 1.62
The mammary myoepithelial cell--Cinderella or ugly sister? Breast Cancer Res (2000) 1.46
Telomere shortening occurs in subsets of normal breast epithelium as well as in situ and invasive carcinoma. Am J Pathol (2004) 1.44
Quantifying cancer progression with conjunctive Bayesian networks. Bioinformatics (2009) 1.37
Genetic relation of lobular carcinoma in situ, ductal carcinoma in situ, and associated invasive carcinoma of the breast. Mol Pathol (2000) 1.34
Demystifying basal-like breast carcinomas. J Clin Pathol (2007) 1.22
The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions. Breast Cancer Res (2003) 1.20
The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Exp Mol Pathol (2009) 1.18
P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. Virchows Arch (2006) 1.13
Differential patterns of allelic loss in estrogen receptor-positive infiltrating lobular and ductal breast cancer. Genes Chromosomes Cancer (2008) 1.10
Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression. Am J Pathol (2012) 1.09
Transcriptomic landscape of breast cancers through mRNA sequencing. Sci Rep (2012) 1.08
Preinvasive breast cancer. Annu Rev Pathol (2010) 1.08
A comprehensive study of chromosome 16q in invasive ductal and lobular breast carcinoma using array CGH. Oncogene (2006) 1.01
Deciphering a subgroup of breast carcinomas with putative progression of grade during carcinogenesis revealed by comparative genomic hybridisation (CGH) and immunohistochemistry. Br J Cancer (2004) 1.00
Adenomyoepithelial tumours and myoepithelial carcinomas of the breast--a spectrum of monophasic and biphasic tumours dominated by immature myoepithelial cells. BMC Cancer (2005) 1.00
Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma. World J Surg Oncol (2007) 0.99
The diagnosis and management of pre-invasive breast disease: promise of new technologies in understanding pre-invasive breast lesions. Breast Cancer Res (2003) 0.99
Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. Br J Cancer (2005) 0.98
Molecular cytogenetic investigations of synchronous bilateral breast cancer. J Clin Pathol (2003) 0.98
Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy. Br J Cancer (2006) 0.97
Genetic characterisation of invasive breast cancer: a comparison of CGH and PCR based multiplex microsatellite analysis. J Clin Pathol (2001) 0.94
Correlation of DNA hypomethylation at pericentromeric heterochromatin regions of chromosomes 16 and 1 with histological features and chromosomal abnormalities of human breast carcinomas. Am J Pathol (2002) 0.94
Mapping loss of heterozygosity in normal human breast cells from BRCA1/2 carriers. Br J Cancer (2006) 0.92
PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma. Clin Cancer Res (2014) 0.89
Breast cancer in European Union: an update of screening programmes as of March 2014 (review). Int J Oncol (2014) 0.88
Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions. Breast Cancer Res (2012) 0.87
Tumour histological grade may progress between primary and recurrent invasive mammary carcinoma. J Clin Pathol (2002) 0.82
Grade of recurrent in situ and invasive carcinoma following treatment of pure ductal carcinoma in situ of the breast. Br J Cancer (2004) 0.80
Intraductal proliferative lesions of the breast-terminology and biology matter: premalignant lesions or preinvasive cancer? Int J Surg Oncol (2012) 0.80
Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion. Mol Oncol (2014) 0.79
Epigenetic Regulation of miRNAs and Breast Cancer Stem Cells. Curr Pharmacol Rep (2015) 0.77
Histopathologic indicators of breast cancer biology: insights from population mammographic screening. Br J Cancer (2005) 0.77
8p deletion is strongly linked to poor prognosis in breast cancer. Cancer Biol Ther (2015) 0.77
c-myc, not her-2/neu, can predict the prognosis of breast cancer patients: how novel, how accurate, and how significant? Breast Cancer Res (2003) 0.77
Dual-color fluorescence in situ hybridization reveals an association of chromosome 8q22 but not 8p21 imbalance with high grade invasive breast carcinoma. PLoS One (2013) 0.77
Genomic heterogeneity of breast tumor pathogenesis. Clin Med Oncol (2009) 0.76
Cytogenetic differences in breast cancer samples between German and Japanese patients. J Clin Pathol (2005) 0.76
Cancer stem cells and early stage basal-like breast cancer. World J Obstet Gynecol (2016) 0.75
Noncoding RNAs in breast cancer. Brief Funct Genomics (2015) 0.75
Genes involved in breast cancer progression: analysis of global changes in gene expression or retroviral tagging? Am J Pathol (2002) 0.75
A 3D in vitro model of the human breast duct: a method to unravel myoepithelial-luminal interactions in the progression of breast cancer. Breast Cancer Res (2017) 0.75
Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. J Breast Health (2013) (2015) 0.75
[Early loss of heterozygosity on chromosome arm 16q in flat epithelial atypia of the breast. Detection by microsatellite analyses]. Pathologe (2008) 0.75
[The significance of "normal tissue" in the development of breast cancer: new concepts of early carcinogenesis]. Pathologe (2006) 0.75
[Genome-wide expression profiling as a clinical tool: are we there yet?]. Pathologe (2009) 0.75
Genome evolution in ductal carcinoma in situ: invasion of the clones. J Pathol (2016) 0.75
Gene-expression profiles in hereditary breast cancer. N Engl J Med (2001) 29.80
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics (1975) 18.25
Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature (2000) 15.53
Flexible regression models with cubic splines. Stat Med (1989) 14.45
The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol (2011) 9.40
Signaling of cell fate decisions by CLAVATA3 in Arabidopsis shoot meristems. Science (1999) 8.61
Data management and analysis for gene expression arrays. Nat Genet (1998) 8.60
The CONSTANS gene of Arabidopsis promotes flowering and encodes a protein showing similarities to zinc finger transcription factors. Cell (1995) 7.76
Dependence of stem cell fate in Arabidopsis on a feedback loop regulated by CLV3 activity. Science (2000) 6.05
Plasmid vectors for the genetic analysis and manipulation of rhizobia and other gram-negative bacteria. Methods Enzymol (1986) 5.58
High frequency mobilization of gram-negative bacterial replicons by the in vitro constructed Tn5-Mob transposon. Mol Gen Genet (1984) 5.35
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol (1996) 5.09
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med (2001) 4.83
Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res (1998) 4.68
The potential for improved teamwork to reduce medical errors in the emergency department. The MedTeams Research Consortium. Ann Emerg Med (1999) 4.59
Trends in reported incidence of primary malignant brain tumors in children in the United States. J Natl Cancer Inst (1998) 4.32
Statistical aspects of prognostic factor studies in oncology. Br J Cancer (1994) 4.22
Bayesian variable selection method for censored survival data. Biometrics (1998) 3.84
Testing for qualitative interactions between treatment effects and patient subsets. Biometrics (1985) 3.71
A molecular link between stem cell regulation and floral patterning in Arabidopsis. Cell (2001) 3.55
Sample size requirements for evaluating a conservative therapy. Cancer Treat Rep (1978) 3.38
Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery (1986) 3.22
Randomized phase II clinical trials. Cancer Treat Rep (1985) 3.19
Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med (1999) 3.03
A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer. J Natl Cancer Inst (2000) 2.95
A new family of RSF1010-derived expression and lac-fusion broad-host-range vectors for gram-negative bacteria. Gene (1990) 2.89
Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol (2001) 2.82
Demonstration of high-fidelity simulation team training for emergency medicine. Acad Emerg Med (1999) 2.82
Extension of the host range of Escherichia coli vectors by incorporation of RSF1010 replication and mobilization functions. J Bacteriol (1985) 2.70
Simulation based teamwork training for emergency department staff: does it improve clinical team performance when added to an existing didactic teamwork curriculum? Qual Saf Health Care (2004) 2.60
Confidence intervals for reporting results of clinical trials. Ann Intern Med (1986) 2.49
Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer (2006) 2.45
High-frequency conjugal plasmid transfer from gram-negative Escherichia coli to various gram-positive coryneform bacteria. J Bacteriol (1990) 2.42
The Comprehensive assessment and Referral Evaluation (CARE)--rationale, development and reliability. Int J Aging Hum Dev (1977) 2.35
Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patterns. J Pathol (2001) 2.33
The development of plasmid-free strains of Agrobacterium tumefaciens by using incompatibility with a Rhizobium meliloti plasmid to eliminate pAtC58. Plasmid (1985) 2.33
A possible vulnerability locus for bipolar affective disorder on chromosome 21q22.3. Nat Genet (1994) 2.30
Repolarization dispersion and sudden cardiac death in patients with impaired left ventricular function. Eur Heart J (1997) 2.27
Mechanisms of DNA double strand break repair and chromosome aberration formation. Cytogenet Genome Res (2004) 2.26
Length biased sampling in etiologic studies. Am J Epidemiol (1980) 2.23
Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J Pathol (1999) 2.22
Statistical model to determine the relationship of response and survival in patients with advanced ovarian cancer treated with chemotherapy. J Natl Cancer Inst (1992) 2.16
Efficacy of selected diagnostic tests for sexually transmitted diseases. JAMA (1976) 2.15
Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease. Nat Med (1999) 2.11
A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med (1984) 2.06
Measures of explained variation for survival data. Stat Med (1990) 2.06
Inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993--the perspective of NIH clinical trialists. Control Clin Trials (1995) 2.04
Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol (2001) 2.01
On the efficiency of targeted clinical trials. Stat Med (2005) 1.99
Practical Bayesian guidelines for phase IIB clinical trials. Biometrics (1994) 1.99
Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene (2001) 1.94
Therapeutic response in phase I trials of antineoplastic agents. Cancer Treat Rep (1986) 1.91
Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst (1991) 1.85
Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep (1977) 1.82
Evidence that childhood acute lymphoblastic leukemia is associated with an infectious agent linked to hygiene conditions. Cancer Causes Control (1998) 1.78
Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol (1999) 1.77
Assessing whether to perform a confirmatory randomized clinical trial. J Natl Cancer Inst (1996) 1.76
Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol (1998) 1.71
A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer (1978) 1.71
The Norton-Simon hypothesis revisited. Cancer Treat Rep (1986) 1.70
Genetics of xanthan production in Xanthomonas campestris: the xanA and xanB genes are involved in UDP-glucose and GDP-mannose biosynthesis. J Bacteriol (1992) 1.68
Statistical design of reverse dye microarrays. Bioinformatics (2003) 1.68
Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis. J Natl Cancer Inst (1993) 1.66
Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma. Oncogene (2007) 1.63
Protected environments and prophylactic antibiotics. A prospective controlled study of their utility in the therapy of acute leukemia. N Engl J Med (1973) 1.61
Parallels between UNUSUAL FLORAL ORGANS and FIMBRIATA, genes controlling flower development in Arabidopsis and Antirrhinum. Plant Cell (1995) 1.60
EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. J Clin Oncol (1999) 1.58
Bypass surgery versus stenting for the treatment of multivessel disease in patients with unstable angina compared with stable angina. Circulation (2002) 1.56
Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute. J Clin Oncol (1997) 1.56
Total occlusion trial with angioplasty by using laser guidewire. The TOTAL trial. Eur Heart J (2000) 1.54
The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med (1978) 1.54
Why predictive indexes perform less well in validation studies. Is it magic or methods? Arch Intern Med (1987) 1.51
Synaptophysin expression in neuroendocrine neoplasms as determined by immunocytochemistry. Am J Pathol (1987) 1.51
Comparison of microarray designs for class comparison and class discovery. Bioinformatics (2002) 1.51
Exercise-induced myocardial ischemia in isolated coronary artery ectasias and aneurysms ("dilated coronopathy"). J Am Coll Cardiol (1999) 1.50
Bayesian subset analysis. Biometrics (1991) 1.50
Percutaneous transluminal therapy of occluded saphenous vein grafts: can the challenge be met with ultrasound thrombolysis? Circulation (1999) 1.50
Causes of inconsistency in diagnosing and classifying intraductal proliferations of the breast. European Commission Working Group on Breast Screening Pathology. Eur J Cancer (2000) 1.50
Tissue microarrays: a new approach for quality control in immunohistochemistry. J Clin Pathol (2002) 1.49
Are placebo-controlled clinical trials ethical or needed when alternative treatment exists? Ann Intern Med (2000) 1.47
Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol (1998) 1.47
A simulation study of cross-validation for selecting an optimal cutpoint in univariate survival analysis. Stat Med (1996) 1.44
Carvedilol for prevention of restenosis after directional coronary atherectomy : final results of the European carvedilol atherectomy restenosis (EUROCARE) trial. Circulation (2000) 1.43
Telomerase is a highly sensitive and specific molecular marker in fine-needle aspirates of breast lesions. J Clin Oncol (1999) 1.43
Osteochondroma: MR imaging of tumor-related complications. Eur Radiol (2000) 1.43
Bicaval versus atrial anastomoses in cardiac transplantation. Right atrial dimension and tricuspid valve function at rest and during exercise up to thirty-six months after transplantation. J Thorac Cardiovasc Surg (1994) 1.41
Identification of Rhizobium plasmid sequences involved in recognition of Psophocarpus, Vigna, and other legumes. J Cell Biol (1986) 1.41
Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases. Am J Pathol (2001) 1.41
Dysregulation of the transcription factors SOX4, CBFB and SMARCC1 correlates with outcome of colorectal cancer. Br J Cancer (2009) 1.40